Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 201 - 217 av 217 resultater
Tid
Selskap
Tittel
Sektor
Kategori
23 Jul 2021
08:00 CEST
ABIVAX
Abivax announces the pricing of its oversubscribed capital increase of EUR 60m and convertible bonds of EUR 25m, totaling eur 85m new financing
20103010 Biotechnology
Change in Capital, Share introduction and issues
23 Jul 2021
08:00 CEST
ABIVAX
Abivax annonce le succès de son augmentation de capital sursouscrite de 60 millions d'euros et de l'émission d'Obligations convertibles de 25 millions d'euros, pour un financement total de 85 millions
20103010 Biotechnology
Other financial transaction
22 Jul 2021
17:45 CEST
ABIVAX
Abivax capital increase and convertible bonds issue to qualified investors for an aggregate amount of approximately EUR 80m
20103010 Biotechnology
Change in Capital
22 Jul 2021
17:45 CEST
ABIVAX
Augmentation de capital et émission d'obligations convertibles d'Abivax réservée à une catégorie d'investisseurs pour un montant total d'environ 80 millions d'euros
20103010 Biotechnology
Other subject
19 Jul 2021
17:59 CEST
ABIVAX
Correction d'un communiqué du 15.07.2021 18:00 CET/CEST - ABIVAX: Nombre d'actions composant le capital social et nombre total de droits de vote
20103010 Biotechnology
Share history
15 Jul 2021
18:00 CEST
ABIVAX
ABIVAX: BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE AU 30 JUIN 2021
20103010 Biotechnology
New
15 Jul 2021
18:00 CEST
ABIVAX
ABIVAX: Nombre d'actions composant le capital social et nombre total de droits de vote
20103010 Biotechnology
Share history
23 Jun 2021
08:00 CEST
ABIVAX
Abivax annonce d'excellents résultats d'efficacité et de tolérance avec 50 mg d'ABX464 dans l'essai clinique de phase 2a pour le traitement de la polyarthrite rhumatoïde
20103010 Biotechnology
Other subject
23 Jun 2021
08:00 CEST
ABIVAX
Abivax reports excellent phase 2a clinical safety and efficacy results with 50mg ABX464 in rheumatoid arthritis
20103010 Biotechnology
Trends / Analyses
16 Jun 2021
18:00 CEST
ABIVAX
ABIVAX: Nombre d'actions composant le capital social et nombre total de droits de vote au 31.05.21.
20103010 Biotechnology
Share history
07 Jun 2021
18:00 CEST
ABIVAX
Abivax releases the results of its June 4, 2021 ordinary annual and extraordinary general meeting
20103010 Biotechnology
General meeting / Board Meeting
07 Jun 2021
18:00 CEST
ABIVAX
Abivax annonce les résultats de son Assemblée générale ordinaire annuelle et extraordinaire du 4 juin 2021
20103010 Biotechnology
General meeting / Board Meeting
24 May 2021
18:30 CEST
ABIVAX
Abivax annonce d'excellents résultats d'efficacité et de tolérance d'ABX464 de l'essai clinique de phase 2b pour le traitement de la rectocolite hémorragique et prévoit d'initier la phase 3
20103010 Biotechnology
Other subject
24 May 2021
18:30 CEST
ABIVAX
Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3
20103010 Biotechnology
Trends / Analyses
24 May 2021
08:49 CEST
ABIVAX
Abivax suspends trading of its shares until the publication of ABX464 Phase 2b results in ulcerative colitis
20103010 Biotechnology
Other subject
24 May 2021
08:47 CEST
ABIVAX
Abivax annonce suspension de la cotation de ses titres dans l'attente de la publication des résultats de l'étude de Phase 2b d'ABX464 dans la rectocolite hémorragique
20103010 Biotechnology
Other subject
19 May 2021
18:00 CEST
ABIVAX
ABIVAX: Nombre d'actions composant le capital social et nombre total de droits de vote au 30.04.21.
20103010 Biotechnology
Share history
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
3
4
5
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva